Inovio

Inovio is a pharmaceutical company that researches, develops and commercializes synthetic vaccines and immune therapies for the treatment of cancer. Read more

Joseph J. Kim's photo - President & CEO of Inovio

President & CEO

Joseph J. Kim

CEO Approval Rating

68/100

Founded:

1979

Status:

PublicIndependent CompanyNASDAQINO

INOVIO TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

CytImmune is seen as one of Inovio's biggest rivals. CytImmune is headquartered in Rockville, Maryland, and was founded in 1988. Like Inovio, CytImmune also works within the Pharmaceuticals sector. CytImmune generates 77% the revenue of Inovio.

bluebird bio is seen as one of Inovio's top competitors. bluebird bio was founded in 1992, and its headquarters is in Cambridge, Massachusetts. bluebird bio operates in the Biotechnology industry. bluebird bio has 932 more employees than Inovio.

Kite Pharma is one of Inovio's top rivals. Kite Pharma is a Private company that was founded in Santa Monica, California in 2009. Kite Pharma operates in the Biotechnology industry. Kite Pharma has 1,719 more employees vs. Inovio.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Dynavax a competitor of Inovio?

Inovio Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$6.5M

Inovio's revenue is the ranked 7th among it's top 10 competitors. The top 10 competitors average 60.8M. Over the last four quarters, Inovio's revenue has grown by 38.9%. Specifically, in Q1 2021's revenue was $ < 1M; in Q4 2020, it was $5.6M; in Q3 2020, it was $ < 1M; in Q2 2020, Inovio's revenue was $ < 1M.

Inovio Acquisitions

No recent acquisitions found related to Inovio

Inovio Funding History

Since Inovio was founded in 1979, it has participated in 15 rounds of funding. In total Inovio has raised $296.4M. Inovio's last funding round was on Apr 2020 for a total of $1.3M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Grant
Apr 2020
$1.3M

Coalition for Epidemic Preparedness Innovations

Grant
Mar 2020
$5M
Grant
Jan 2020
$9M
Debt
Dec 2019
$4M
-
Grant
Sep 2019
--

Since Inovio was founded in 1979, it has participated in 15 rounds of funding. In total Inovio has raised $296.4M. Inovio's last funding round was on Apr 2020 for a total of $1.3M

Inovio Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Geneos is a pharmaceutical company that researches and develops immunotherapeutics for the treatment of cancer.
$12M
Mar 02, 2021
Series A
-
Geneos is a pharmaceutical company that researches and develops immunotherapeutics for the treatment of cancer.
$10.5M
Feb 20, 2019
Series A
-

Inovio News

May 11, 2021Medical Buyer

Inovio reports first quarter 2021 financial results

INOVIO, a biotechnology company focused on rapidly bringing to market precisely designed DNA medicine... See more »
May 11, 2021The Business Journals: Philadelphia

Inovio shifts focus to 'huge' global opportunities for its experimental Covid-19 vaccine

The company's stock opened at its lowest price of the year Tuesday.... See more »
April 27, 2021BioSpace

INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021

INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after... See more »
April 26, 2021Pharmabiz

INOVIO planning for exUS global phase 3 trial for its Covid19 vaccine candidate, INO4800

INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to tre... See more »
April 23, 2021The Business Journals: Philadelphia

Inovio stock plunges after U.S. government pulls funding for late-stage testing of Covid-19 vaccine candidate

The Plymouth Meeting biotechnology company has been working on its potential Covid-19 vaccine since e... See more »
April 23, 2021Markets Insider

Inovio Stock Slumps After Plans To Exclude US For COVID-19 Vaccine Candidate's Global Trial

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares dived in the premarket in reaction to the company's p... See more »

Inovio Press Releases

March 4, 2021StreetInsider

INOVIO to Present at Upcoming Investor Conferences in March

PLYMOUTH MEETING, Pa., March 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company fo... See more »
January 25, 2021PR Newswire

INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

PLYMOUTH MEETING, Pa., Jan. 25, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a bi... See more »
June 26, 2020centralcharts

Inovio Pharmaceuticals, Inc. - INO Stock Chart Technical Analysis for 06-26-2020

News videos - Inovio Pharmaceuticals, Inc. - INO Stock Chart Technical Analysis for 06-26-2020 - Publ... See more »
June 25, 2020PR Newswire

INOVIO Expands Senior Management Team

PLYMOUTH MEETING, Pa., June 25, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has appoi... See more »
May 14, 2020PR Newswire

INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment

PLYMOUTH MEETING, Pa., May 14, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) today announced that 85 perc... See more »
May 12, 2020centralcharts

FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Inovio Pharmaceuticals - INO

INOVIO 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND IN... See more »

Inovio Videos

January 15, 2019Inovio Youtube Channel

"Inovio - Infectious Diseases" on YOUTUBE

January 15, 2019Inovio Youtube Channel

"Inovio - Immuno-Oncology" on YOUTUBE

January 26, 2017Inovio Youtube Channel

"Welcome to Inovio 2017" on YOUTUBE

September 2, 2015Inovio Youtube Channel

"Cancer Cell Destruction" on YOUTUBE

June 11, 2015Inovio Youtube Channel

"VGXI Congressional Visit" on YOUTUBE

Social Media

Inovio Headquarters

660 West Germantown Pike Suite 110

Plymouth Meeting, Pennsylvania19462

1-267-440-4200

Driving Directions »

Trending Companies

Inovio Summary

ABOUT

Overview

Inovio is a pharmaceutical company that researches, develops and commercializes synthetic vaccines and immune therapies for the treatment of cancer. Inovio was founded in 1979. Inovio's headquarters is located in Plymouth Meeting, Pennsylvania, USA 19...

CEO

Inovio's President & CEO, Joseph J. Kim, currently has an approval rating of 68%. Inovio's primary competitors are CytImmune, bluebird bio & Kite Pharma.

Website

inovio.com

Frequently Asked Questions about Inovio

  1. When was Inovio founded?

    Inovio was founded in 1979
  2. Who is Inovio's CEO?

    Inovio's CEO is Joseph J. Kim
  3. How much revenue does Inovio generate?

    Inovio generates $6.5M in revenue
  4. How much funding does Inovio have?

    Inovio has historically raised $296.4M in funding
  5. Where is Inovio's headquarters?

    Inovio's headquarters is in Plymouth Meeting Pennsylvania, USA
  1. How many employees does Inovio have?

    Inovio has 281 employees
  2. What sector does Inovio operate in?

    Inovio is in Pharmaceuticals, Biotechnology
  3. Who are Inovio's competitors?

    Inovio's top competitors are CytImmune, bluebird bio, Kite Pharma
  4. Who has Inovio invested in?

    Inovio's has invested in companies such as Geneos Therapeutics, Geneos Therapeutics